THERAPEUTIC AGENT FOR COLITIS ULCEROSA

PURPOSE:To provide a therapeutic agent for colitis ulcerosa, containing cell bodies of a Lactobacillus bifidus as the active component, excellent in its effect and capable of large volume administration with safety. CONSTITUTION:This therapeutic agent contains cell bodies of a Lactobacillus bifidus [e.g. Bifidobacterium longum No7 (FERMP-13610)] belonging to Bifidobacterium as the active component. The Lactobacillus bifidus is an enterobacterium of human and animals and very important for maintenance of health condition from old times and this therapeutic agent has various effects, e.g. inhibition of production of harmful substances such as a cancerogenic substance, prevention of intestinal infection with a pathogen, prevention of growth of harmful enterobacteria, synthesis of vitamin B1, B2, B6, B12 and K, promotion of digestion and absorption and immunological enhancement. The dosage is >=1X10 /day per an adult on viable cell base. This therapeutic agent is excellent in safety, the therapeutic effect and prevention of recurrence and can be used in combination with salazopyrin or prednizolone.